Alzamend Neuro, Inc.
50 W. Broadway
Salt Lake City
About Alzamend Neuro, Inc.Alzamend Neuro is a development stage biotechnology company which has licensed a patented mutant peptide developed by Dr. Chuanhai Cao at the college of Pharmacy of the University of South Florida (USF) and USF- Health Byrd Alzheimer’s Institute to develop a cell based therapeutic vaccine as an immunotherapy to prevent or slowdown Alzheimer’s disease. This therapy is not only target on the pathological molecule that is associated to AD, but also is able to fix the impaired immune system associated to AD development
CEO: Phil Mansour
CTO: William B. Horne
Chairman: Milton “Todd” Ault
Please click here for Alzamend Neuro's job opportunities.
19 articles with Alzamend Neuro, Inc.
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
Alzamend Neuro, Inc. announced that it has submitted a pre-IND meeting request for AL002 and supporting briefing documents to the Center for Biological Evaluation and Research of the U.S. Food and Drug Administration.
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), today announced receipt of U.S. Food and Drug Administration (“FDA”) study may proceed letter for a Phase 1 study under the Company’s Investigational New Drug application for AL001, a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s disease.
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, announced that it has received positive toxicology results for AL002 in a good laboratory practices toxicology study using a transgenic mouse model of Alzheimer’s disease.
Alzamend Neuro®, Inc. announced that its Chairman of the Board, William B. Horne, its CEO, Stephan Jackman and its Founder and Chairman Emeritus, Milton “Todd” Ault, III, will join members of the Company’s management, Board of Directors and founding stockholders to ring the opening bell at the Nasdaq stock exchange on Monday, July 12, 2021 at 9:30 am ET at the Nasdaq MarketSite at Times Square.
Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer’s Disease
Ault Global Holdings, Inc. a diversified holding company, announced that Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, submitted an investigational new drug application to the FDA for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021.
Alzamend Neuro®, Inc., a preclinical stage biopharmaceutical company, announced that it submitted an investigational new drug application to the U.S. Food and Drug Administration for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021.
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
Ault Global Holdings, Inc., a diversified holding company, announced that Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, priced its initial public offering of 2,500,000 shares of common stock at a price to the public of $5.00 per share for gross proceeds of $12.5 million from the offering.
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
Alzamend Neuro®, Inc. announces an agreement to sell $10,000,000 of its securities to Digital Power Lending LLC, a subsidiary of Ault Global Holdings, Inc.
Alzamend Neuro®, Inc. (“ Alzamend ”) today announced that it has entered into a securities purchase agreement with Digital Power Lending, LLC (“ DPL ”), a wholly owned subsidiary of Ault Global Holdings, Inc. (“ AGH ”), a related party. Pursuant to the securities purchase agreement, DPL agreed to invest an aggregate of $10,000,000 in our common stock and warrants.
DPW Holdings Announces Alzamend Neuro®, Inc.’s Confidential Submission of a Draft Registration Statement Relating to the Proposed Initial Public Offering of Its Common Stock
DPW Holdings Announces Alzamend Neuro ® , Inc.’s Confidential Submission of a Draft Registration Statement Relating to the Proposed Initial Public Offering of Its Common Stock NEWPORT BEACH, Calif.--( BUSINESS WIRE )-- DPW Holdings, Inc. (NYSE American: DPW), a diversified holding company (“ DPW ,” or the “ Company ”), announced that Alzamend Neuro®, Inc. (“ Alzamend ”) today announced that it has confidentially submitted a draft registration statement on
Alzamend Neuro®, Inc. Registration is Closing to Join the Shareholder and Investor Conference Call and Webcast Set for Tomorrow, November 17, 2020 to Provide Update and Plans for 2021
Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) reminds shareholders, investors and all interested parties that mandatory registration is closing Tuesday morning for the conference call and webcast to be held that day November 17th at 5:00pm ET (2:00pm PT) led by Alzamend’s Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Alzamend’s CEO and Director.
New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association.
Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its Scientific Advisory Board.
Alzamend Neuro™ Announces Senior Management to Participate in the 2019 Alzheimer’s Association International Conference®
Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that its senior management team led by Stephan Jackman, the Company’s CEO, and Ken Cragun, the Company’s CFO, will be participating in the annual Alzheimer’s Association International Conference® being held in Los Angeles, CA, from July 12 through July 18, 2019 at the L.A. Convention Center
Appoints Dr. Thomas Wisniewski, Leading Pioneer in Alzheimer’s Disease
The company has selected TAMM Net as FDA consultant to lead regulatory actions for USF treatment.
Alzamend Neuro Release: University of South Florida Researcher Develops Therapeutic Vaccine To Combat Alzheimer’s Disease And Neurodegenerative Disorders